NFLIS Reports on Deoxymethoxetamine (3'-methyl-2-oxo-PCE, DMXE, 3D-MXE)
| Tracking # |
25-00545-F |
| Submitted | Feb. 26, 2025 |
| Due | March 26, 2025 |
| Est. Completion | None |
MuckRock users can file, duplicate, track, and share public records requests like this one. Learn more.
Communications
From: Robert Delaware
To Whom It May Concern:
Pursuant to the Freedom of Information Act, I hereby request the following records:
This request is for the release of any drug reports compiled by the NFLIS (National Forensic Laboratory Information System) regarding Deoxymethoxetamine (3'-methyl-2-oxo-PCE, DMXE, 3D-MXE).
https://en.wikipedia.org/wiki/Deoxymethoxetamine
According to the September 2024 NFLIS-Drug bulletin, Deoxymethoxetamine was reported by a lab in the state Maryland to the National Forensic Laboratory Information System for the first time in 2024. The drug, publicly identified by the government as a hallucinogen, was reported to the DEA's NFLIS sometime between January 1st 2024 and September 30th 2024. A copy of the September 2024 NFLIS-Drug bulletin that mentions Deoxmethoxetamine should be attached to this request.
This is a request for any documents, reports, memorandum, or anything that could reasonably be construed as "relevant documents" related to Deoxmethoxetamine created by the NFLIS during this period. Please conduct a search any "evaluations for scheduling" or "recommendations for scheduling" or "reports to NFLIS" or "reports from NFLIS" regarding Deoxymethoxetamine aka "3'-methyl-2-oxo-PCE", "DMXE" and "3D-MXE".
If the Drug Enforcement Agency cannot fulfill certain parts of this request or certain portions must be redacted please provide any reasonable segregable portion of a requested record after removing or redacting those portions claimed to be exempt, explain in writing the justification for redacting the record, indicate the extent of any redactions on the portion of the record which is made available or published and where technically feasible indicate on the redacted portion itself the specific exemption(s) claimed.
Thank you for the Drug Enforcement Agency's commitment to transparency, and I look forward to working together until this request is resolved.
The requested documents will be made available to the general public, and this request is not being made for commercial purposes.
In the event that there are fees, I would be grateful if you would inform me of the total charges in advance of fulfilling my request. I would prefer the request filled electronically, by e-mail attachment if available or CD-ROM if not.
Thank you in advance for your anticipated cooperation in this matter. I look forward to receiving your response to this request within 20 business days, as the statute requires.
Sincerely,
Robert Delaware
From: Drug Enforcement Administration
Dear Robert Delaware,
Your request has been received by the DEA. The request has been assigned tracking # 25-00545-F, please log into your account and review your submission.
The application address is https://ifa.dea.gov/foia.
Thank you,
DEA
From: Drug Enforcement Administration
Dear Robert Delaware,
The status of your FOIA request #25-00545-F has been updated to the following status 'In Process'. To log into the DEA Public Access Link click on the Application URL below.
Sincerely,
DEA
From: Drug Enforcement Administration
Dear Robert Delaware: This e-mail responds to your Freedom of Information Act/Privacy Act (FOIA/PA) request dated February 27, 2025, received by the Drug Enforcement Administration (DEA), FOIA/PA Unit, seeking access to DEA records. Your request has been opened and assigned the following case number: 25-00545-F. Please include this case number when communicating with this office. The records you seek require searches in another office or offices, and so your request falls within "unusual circumstances." See 5 U.S.C. § 552(a)(6)(B)(i)-(iii). Because of these unusual circumstances, we are extending the time limit to respond to your request beyond the ten additional days provided by the statute. We have not yet completed a search to determine whether there are records within the scope of your request. The time needed to process your request will necessarily depend on the complexity of our records search and on the volume and complexity of any records located. For your information, this office assigns incoming requests to one of three tracks: simple, complex, or expedited. Each request is then handled on a first-in, first-out basis in relation to other requests in the same track. Simple requests usually receive a response in approximately one month, whereas complex requests take longer than a month to complete. At this time, your request has been assigned to the complex track.
If you have any questions, you may contact our FOIA Requester Service Center at (571) 776-2300, or e-mail your correspondence to DEA.FOIA@dea.gov. In addition, you may contact our FOIA Public Liaison at (571) 776-2300 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, Room 2510, 8601 Adelphi Road, College Park, Maryland 20740-6001; e-mail at ogis@nara.gov; telephone at (202) 741-5770; toll free at 1-877-684-6448; or facsimile at (202) 741-5769. Sincerely,
FOIA/PA Unit FOIA & Information Law Section Office of Chief Counsel Drug Enforcement Administration
PRIVACY ACT NOTICE: This e-mail (including any attachments herein) may contain personal and privileged information that requires protection in compliance with the Privacy Act of 1974 (5 U.S.C. § 552a). Any use of this information by anyone other than the intended recipient is prohibited. If you have received this communication in error, please immediately delete all copies of this information and notify me by e-mail. The use, dissemination, distribution, or reproduction of this communication by unintended recipients is not authorized and may be unlawful.
-
_EXTERNAL Freedom of Information Act Request NFLIS Reports on Deoxymethoxetamine (3'-methyl-2-oxo-PCE DMXE 3D-MXE)